June 29, 2018
CHMP recommends approval of Sanofi’s Cablivi
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: aTTP
July 26, 2017
Ablynx’s Nanobody Fast Track listed by the US FDA, third phase study report in 2017
Ablynx was granted Fast Track designation for caplacizumab, by the that the U.S. Food and Drug Administration (FDA). That’s the company’s first-in-class anti-von Willebrand factor (vWF) Nanobody developed for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
February 6, 2017
Ablynx submits its thrombosis antibody to EMA
Ablynx has applied its caplacizumab to European Medicines Agency for approval to use it for a form of blod clotting disorder.